Switch theme
Sign up to access all valuation multiples
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
2000
40
LTM Revenue n/a
LTM EBITDA -$5.4M
$197M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oryzon Genomics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$5.4M.
In the most recent fiscal year, Oryzon Genomics achieved revenue of n/a and an EBITDA of -$4.4M.
Oryzon Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oryzon Genomics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | $10.6M | $16.4M | XXX | XXX | XXX |
| Gross Margin | Infinity% | Infinity% | XXX | XXX | XXX |
| EBITDA | -$5.7M | -$4.4M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$5.0M | -$4.5M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oryzon Genomics's stock price is EUR 3 (or $3).
Oryzon Genomics has current market cap of EUR 180M (or $193M), and EV of EUR 183M (or $197M).
See Oryzon Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $197M | $193M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oryzon Genomics has market cap of $193M and EV of $197M.
Oryzon Genomics's trades at n/a LTM EV/Revenue multiple, and -36.6x LTM EBITDA.
Analysts estimate Oryzon Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oryzon Genomics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $197M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -45.2x | XXX | XXX | XXX |
| P/E | -53.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOryzon Genomics's NTM/LTM revenue growth is n/a
Oryzon Genomics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Oryzon Genomics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oryzon Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oryzon Genomics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oryzon Genomics acquired XXX companies to date.
Last acquisition by Oryzon Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Oryzon Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oryzon Genomics founded? | Oryzon Genomics was founded in 2000. |
| Where is Oryzon Genomics headquartered? | Oryzon Genomics is headquartered in Spain. |
| How many employees does Oryzon Genomics have? | As of today, Oryzon Genomics has 40 employees. |
| Is Oryzon Genomics publicy listed? | Yes, Oryzon Genomics is a public company listed on MAD. |
| What is the stock symbol of Oryzon Genomics? | Oryzon Genomics trades under ORY ticker. |
| When did Oryzon Genomics go public? | Oryzon Genomics went public in 2015. |
| Who are competitors of Oryzon Genomics? | Similar companies to Oryzon Genomics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oryzon Genomics? | Oryzon Genomics's current market cap is $193M |
| What is the current EBITDA of Oryzon Genomics? | Oryzon Genomics's last 12-month EBITDA is -$5.4M. |
| What is the current EV/EBITDA multiple of Oryzon Genomics? | Current EBITDA multiple of Oryzon Genomics is -36.6x. |
| Is Oryzon Genomics profitable? | Yes, Oryzon Genomics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
